PubMed · 3855382
High-dose ifosfamide in advanced osteosarcoma.
Abstract
In a prospective study, 18 evaluable patients with recurrent osteosarcoma were treated with ifosfamide, 1.8 g/m2 daily for 5 consecutive days. Courses were repeated every 4 weeks. Additional mesna (2-mercaptoethane sulfonate) was given to prevent urotoxicity. All patients had measurable lung deposits and all but one had been pretreated with various cytotoxic agents. Six patients (33%) showed therapeutic response, two complete and four partial, with a median duration of 5.5 months (range, 3-47+). Toxicity included myelosuppression, alopecia, nausea, and vomiting. No severe urotoxicity or central nervous system toxicity was observed. Thus, high-dose ifosfamide in combination with mesna seems to be a safe and effective agent for the chemotherapy of osteosarcoma.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
C Marti, T Kroner, W Remagen, W Berchtold, M Cserhati, M Varini. 1985. High-dose ifosfamide in advanced osteosarcoma.. https://pubmed.ncbi.nlm.nih.gov/3855382/
Cite the original work for its findings. Save a collection to share your selection of sources.